Pulmonary Arterial Hypertension

Sildenafil has the potential to improve hemodynamics and exercise capacity for up to 12 months in children with Pulmonary arterial hypertension (PAH), and this medication can be compounded as a stable oral suspension.

Circulation. 2005 Jun 21;111(24):3274-80
Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study.
Click here to access the PubMed abstract of this article.

Am J Health Syst Pharm. 2006 Feb 1;63(3):254-7
Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children.
Click here to access the PubMed abstract of this article.

Compounding content © 2005-2014 , Storey Marketing. All rights reserved.


Leave a Reply